logo-loader
viewZynerba Pharmaceuticals

Zynerba announces top-line results from CONNECT-FX study of Zygel CBD gel in children and adolescents with Fragile X syndrome

The Pennsylvania company intends to meet with the FDA regarding a regulatory path forward for Zygel.

Zynerba Pharmaceuticals - Zynerba Pharmaceuticals Inc announces top-line results from CONNECT-FX clinical study of CBD in children and adolescents with Fragile X syndrome
The study found that some patients appear to benefit from treatment of their behavioral symptoms with Zygel

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) announced Tuesday top-line results from the 14-week CONNECT-FX clinical study of cannabidiol (CBD) in children and adolescents with Fragile X syndrome.

The multi-national, randomized, double-blind, placebo-controlled trial assessed the efficacy and safety of the Zygel CBD gel as a treatment for behavioral symptoms of the syndrome (FXS) in 212 patients.

In a statement, Zynerba said Zygel did not achieve statistical significance versus placebo in the primary endpoint of improvement in the Social Avoidance subscale of the Aberrant Behavior Checklist – Community FXS (ABC-CFXS). 

READ: Zynerba price target boosted to $11 by Roth on positive results from ASD clinical trial with CBD skin gel Zygel

The company also said Zygel did not demonstrate statistical significance versus placebo in the three key secondary endpoints, which were the change from baseline to the end of the treatment period in the Irritability subscale score of the ABC-CFXS, the Socially Unresponsive/Lethargic subscale score of the ABC-CFXS and Improvement in Clinical Global Impression (CGI-I).

Zynerba said a pre-planned ad hoc analysis of the most severely impacted patients in the trial -- as defined by patients having at least 90% methylation (full methylation) of the impacted FMR1 gene -- demonstrated that patients receiving Zygel achieved statistical significance in the primary endpoint of improvement at 12 weeks of treatment in the Social Avoidance subscale of the ABC-CFXS compared to placebo. 

This group comprised 80% of the patients enrolled in the CONNECT-FX study, and the company said it believes that full methylation occurs in about 60% of the overall FXS patient population. 

Meeting with FDA

Based on this analysis, Devon, Pennsylvania-based Zynerba said it intends to meet with the US Food and Drug Administration regarding a regulatory path forward for Zygel.

Fragile X is a genetic condition caused by a mutation in the FMR1 gene. The mutation causes the X chromosome to appear constricted, or fragile, under a microscope, hence its name. Patients with Fragile X often have learning disabilities and other cognitive impairments.

“This study identified a key population of patients who appear to benefit from treatment of their behavioral symptoms of FXS with Zygel,” said Dr Randi Hagerman, an investigator in the clinical trial and medical director and endowed chair in Fragile X research at UC Davis. “Zygel has the potential to be an important therapeutic option for the most severely impacted patients with Fragile X.”

Zynerba CEO Armando Anido said the test results may offer the company a “pathway towards licensure” and that it will seek to discuss the result with the FDA “as soon as possible.”

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: Zynerba Pharmaceuticals

Price: 3.62 USD

NASDAQ:ZYNE
Market: NASDAQ
Market Cap: $90.2 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Zynerba Pharmaceuticals named herein, including the promotion by the Company of Zynerba Pharmaceuticals in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Zynerba Pharmaceuticals well-funded for its CBD clinical trials into 2021

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) CEO Armando Anido tells Proactive Investors the Pennsylvania-based biotech has $59.8 million to fund clinical trials for its cannabis-derived treatments 'beyond major milestones' into 2021. Zynerba is on track to report top-line results from tests...

on 03/12/2019

3 min read